Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (locally advanced) and is unable to be operated on (inoperable). Tamoxifen works by blocking the effects of estrogen in the breast. This may help stop the growth of tumor cells that need estrogen to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving tamoxifen and pegylated liposomal doxorubicin together may work better in treating patients with metastatic or inoperable, locally advanced triple negative breast cancer than giving either of these drugs alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi potrójnie negatywny, który się rozprzestrzenił lub jest nieoperacyjny, po co najmniej dwóch wcześniejszych leczeniach w tej fazie choroby.
- •Potwierdzona specyficzna zmiana genetyczna w komórkach raka (TP53).
- •Badania wykazały brak receptorów estrogenowych (ER ≤ 10%) i progesteronowych (PgR) w komórkach raka.
- •Rak nie zawiera białka HER2.
- •Pacjentki muszą mieć co najmniej 18 lat.
- •Ogólny stan zdrowia pacjentki pozwala na aktywność (status ECOG 0-1).
- •Odpowiednia liczba białych krwinek (neutrofile ≥ 1500/µL).
- •Odpowiedni poziom hemoglobiny (≥ 9 g/dL) i płytek krwi (≥ 100 000/µL).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Roswell Park Cancer Institute
Buffalo, United States
Trial contact
Sheheryar Kabraji
Sheheryar Kabraji
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.